Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody
AUTOR(ES)
Nowakowski, A.
FONTE
National Academy of Sciences
RESUMO
The botulinum neurotoxins (BoNTs) cause the paralytic human disease botulism and are one of the highest-risk threat agents for bioterrorism. To generate a pharmaceutical to prevent or treat botulism, monoclonal antibodies (mAbs) were generated by phage display and evaluated for neutralization of BoNT serotype A (BoNT/A) in vivo. Although no single mAb significantly neutralized toxin, a combination of three mAbs (oligoclonal Ab) neutralized 450,000 50% lethal doses of BoNT/A, a potency 90 times greater than human hyperimmune globulin. The potency of oligoclonal Ab was primarily due to a large increase in functional Ab binding affinity. The results indicate that the potency of the polyclonal humoral immune response can be deconvoluted to a few mAbs binding nonoverlapping epitopes, providing a route to drugs for preventing and treating botulism and diseases caused by other pathogens and biologic threat agents.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=123259Documentos Relacionados
- Clostridium botulinum neurotoxin.
- Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.
- Epitope Mapping of Neutralizing Botulinum Neurotoxin A Antibodies by Phage Display
- Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.
- Nature of intracellular type A botulinum neurotoxin.
